Guardant Health, Inc. $GH Stake Reduced by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. cut its holdings in Guardant Health, Inc. (NASDAQ:GH) by 73.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,085 shares of the company’s stock after selling 56,516 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Guardant Health were worth $2,051,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Allworth Financial LP raised its holdings in Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock worth $53,000 after buying an additional 138 shares during the period. Eastern Bank raised its holdings in Guardant Health by 6.9% during the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after buying an additional 139 shares during the period. Xponance LLC raised its holdings in Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after buying an additional 199 shares during the period. Danske Bank A S raised its holdings in Guardant Health by 20.0% during the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after buying an additional 200 shares during the period. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna raised its holdings in Guardant Health by 1.9% during the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock worth $1,124,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wolfe Research assumed coverage on Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective on the stock. BTIG Research set a $160.00 price objective on Guardant Health and gave the stock a “buy” rating in a report on Wednesday, May 27th. Citigroup boosted their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $141.95.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. The trade was a 4.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the transaction, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. This trade represents a 47.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 449,238 shares of company stock worth $51,164,492. Company insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

NASDAQ:GH opened at $129.82 on Tuesday. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $135.00. The stock’s 50-day moving average is $104.23 and its two-hundred day moving average is $102.22. The stock has a market cap of $17.21 billion, a PE ratio of -38.29 and a beta of 1.61.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.